“…To our knowledge, this is the first study to fully characterize an impaired contractile phenotype in the pre-clinical rodent model of Barth syndrome and the potential efficacy of dietary supplemental LA to reverse this phenotype. Similar to previous studies, administration of doxycycline to TazKD mice in utero and post-weaning resulted in decreased skeletal muscle Taz mRNA, protein, CL content, CL 18:2n6 composition, and increased MLCL:CL ratio ( Acehan et al, 2011 ; Soustek et al, 2011 ; Ikon et al, 2018 ; Johnson et al, 2018 ; Goncalves et al, 2021 ), along with reduced weight gain ( Acehan et al, 2011 ; Cole et al, 2016 ; Ikon et al, 2018 ; Johnson et al, 2018 ; Goncalves et al, 2021 ). The main findings are (1) TazKD soleus demonstrated slower force development and relaxation in vitro as key contributors to this impaired contractile phenotype, (2) the impaired contractile phenotype seen in vitro in TazKD compared to WT did not translate to altered muscle function in vivo , and (3) supplemental LA attenuated, to some degree, soleus in vitro impaired contractile phenotype in TazKD mice, which appears to not be fully mediated by CL content and composition.…”